Michael J. Gast
Profile
Michael J.
Gast had been Executive Vice President and Chief Medical Officer of Genaera Corp.
since October 2007.
Previously, he served as Executive Vice President of Clinical Research and Development of Genaera since January 2007, as Senior Vice President of Clinical Research and Development from March 2006 to December 2006, as Chief Medical Officer from February 2005 to July 2005 and a Consultant from November 2005 to March 2006.
Dr. Gast worked for Wyeth Pharmaceuticals, where he was Vice President of Scientific Affairs-Global Medical Affairs.
He served as Vice President for Women's Health Clinical Research and Development of Wyeth Pharmaceuticals.
Dr. Gast served as a Director of the Division of Reproductive Endocrinology and Infertility of Washington University and a Director of the Endocrine Clinical Laboratories Department.
He received an MD from The Ohio State University College of Medicine in 1973 and a PhD in Molecular Biology from Washington University in 1981.
Former positions of Michael J. Gast
| Companies | Position | End |
|---|---|---|
Wyeth Pharmaceuticals LLC
 Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA. | Chief Tech/Sci/R&D Officer | - |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | Corporate Officer/Principal | - |
Genaera Corp.
 Genaera Corp. Pharmaceuticals: MajorHealth Technology Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA. | Chief Tech/Sci/R&D Officer | - |
Training of Michael J. Gast
| The Ohio State University | Doctorate Degree |
| University of Washington | Doctorate Degree |
Experiences
Positions held
Linked companies
| Private companies | 2 |
|---|---|
Genaera Corp.
Genaera Corp. Pharmaceuticals: MajorHealth Technology Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA. | Health Technology |
Wyeth Pharmaceuticals LLC
Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA. | Health Technology |
- Stock Market
- Insiders
- Michael J. Gast
